Connor, Clark & Lunn Investment Management (CC&L) Portfolio holdings
AUM
$28.4B
1-Year Return
37.22%
This Quarter Return
-5.67%
1 Year Return
+37.22%
3 Year Return
+93.7%
5 Year Return
+199.54%
10 Year Return
+398.51%
AUM
$15.3B
AUM Growth
-$1.2B
(-7.3%)
Cap. Flow
+$44.4M
Cap. Flow
% of AUM
0.29%
Top 10 Holdings %
Top 10 Hldgs %
32.45%
Holding
1,302
New
280
Increased
463
Reduced
337
Closed
213
Top Buys
| 1 |
Canadian Pacific Kansas City
CP
|
$68.4M |
| 2 |
TSMC
TSM
|
$61.2M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
$52.6M |
| 4 |
Canadian National Railway
CNI
|
$50.8M |
| 5 |
Restaurant Brands International
QSR
|
$38.3M |
Top Sells
| 1 |
Scotiabank
BNS
|
$66.2M |
| 2 |
Suncor Energy
SU
|
$55.5M |
| 3 |
BCE
BCE
|
$44.3M |
| 4 |
Bank of Montreal
BMO
|
$42.3M |
| 5 |
Eli Lilly
LLY
|
$38.1M |
Sector Composition
| 1 | Financials | 26.02% |
| 2 | Industrials | 15.28% |
| 3 | Energy | 13.03% |
| 4 | Technology | 11.16% |
| 5 | Materials | 8.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Crawford & Co Class A
CRD.A
$540M
| $185K | ﹤0.01% |
32,305
-594
| -2% | -$3.4K |
|
1002
RLX Technology
RLX
$3.18B
| $181K | ﹤0.01% |
171,958
+71,380
| +71% | +$75.1K |
|
|
AVEO
1003
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $177K | ﹤0.01% |
+21,563
| New | +$177K |
|
1004
Quad
QUAD
$334M
| $176K | ﹤0.01% |
68,904
-1,635
| -2% | -$4.18K |
|
1005
LendingClub
LC
$1.9B
| $175K | ﹤0.01% |
15,830
-67,248
| -81% | -$743K |
|
1006
Arbutus Biopharma
ABUS
$805M
| $173K | ﹤0.01% |
+90,497
| New | +$173K |
|
|
PENG
1007
Penguin Solutions, Inc. Ordinary Shares
PENG
$1.3B
| $166K | ﹤0.01% |
+10,477
| New | +$166K |
|
1008
Oric Pharmaceuticals
ORIC
$1.06B
| $163K | ﹤0.01% |
50,809
+29,746
| +141% | +$95.4K |
|
|
CMCM
1009
Cheetah Mobile
CMCM
$196M
| $162K | ﹤0.01% |
80,762
-16,923
| -17% | -$33.9K |
|
1010
First Commonwealth Financial
FCF
$1.87B
| $162K | ﹤0.01% |
+12,579
| New | +$162K |
|
1011
Akebia Therapeutics
AKBA
$785M
| $161K | ﹤0.01% |
510,102
+283,332
| +125% | +$89.4K |
|
1012
VirnetX
VHC
$78.5M
| $159K | ﹤0.01% |
6,801
+449
| +7% | +$10.5K |
|
1013
Hercules Capital
HTGC
$3.49B
| $158K | ﹤0.01% |
+13,658
| New | +$158K |
|
1014
OneSpan
OSPN
$583M
| $154K | ﹤0.01% |
17,930
-17,325
| -49% | -$149K |
|
|
PVLA
1015
Palvella Therapeutics, Inc. Common Stock
PVLA
$616M
| $154K | ﹤0.01% |
1,671
+565
| +51% | +$52.1K |
|
1016
Amtech Systems
ASYS
$91.9M
| $153K | ﹤0.01% |
18,014
-646
| -3% | -$5.49K |
|
|
BCEL
1017
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $153K | ﹤0.01% |
97,264
+42,963
| +79% | +$67.6K |
|
1018
Applied Optoelectronics
AAOI
$1.5B
| $152K | ﹤0.01% |
+55,918
| New | +$152K |
|
1019
Precision BioSciences
DTIL
$59.8M
| $152K | ﹤0.01% |
3,893
+488
| +14% | +$19.1K |
|
1020
Zymeworks
ZYME
$1.14B
| $151K | ﹤0.01% |
24,583
+8,296
| +51% | +$51K |
|
1021
Atara Biotherapeutics
ATRA
$90.7M
| $149K | ﹤0.01% |
1,572
-2,624
| -63% | -$249K |
|
1022
Companhia Siderúrgica Nacional
SID
$1.99B
| $149K | ﹤0.01% |
+62,756
| New | +$149K |
|
1023
HUTCHMED
HCM
$2.74B
| $148K | ﹤0.01% |
+16,664
| New | +$148K |
|
1024
Iovance Biotherapeutics
IOVA
$901M
| $146K | ﹤0.01% |
+15,250
| New | +$146K |
|
1025
Black Diamond Therapeutics
BDTX
$167M
| $140K | ﹤0.01% |
82,881
+70,551
| +572% | +$119K |
|